Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03944577
Other study ID # 0104-19-FB
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date July 15, 2019
Est. completion date March 28, 2023

Study information

Verified date May 2024
Source University of Nebraska
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Coronary allograft vasculopathy (CAV) is diffusely accelerated atherosclerosis of a transplanted heart. Evolocumab (Repatha) is an FDA-approved drug for lowering low density lipoprotein (LDL) in patients who have not received a heart transplant. This drug works as a PCSK9-inhibitor. The primary objective of this study is to measure the impact of PCSK9-inhibitors on serum LDL in heart transplant patients with CAV after 12 weeks compared to baseline.


Description:

Heart transplant remains the treatment of choice for patients with advanced heart failure. Coronary allograft vasculopathy (CAV) is diffusely accelerated atherosclerosis of the donor heart, and limits long term survival after transplant. The pathophysiology of CAV is complex and involves smooth muscle proliferation, inflammatory infiltrates, and lipid deposition. To date, only statin therapy has reduced CAV-related mortality. PCSK9 inhibitors are a new lipid lowering therapy shown to reduce cardiovascular clinical events in patients with coronary artery disease. We hypothesize that PCSK9 inhibition via evolocumab will significantly lower low density lipoprotein (LDL) and be well-tolerated in transplant patients with CAV. This phase II, open label, single center trial with enroll up to 40 heart transplant patients with CAV for treatment with evolocumab for one year. The primary outcome will be percent change in LDL at 12 weeks. Secondary outcomes will include change in CAV progression, impact of evolocumab on immunosuppression regimens and transplant rejection, and change in serum lipids after 52 weeks. Results of this study are intended to provide safety data in heart transplant patients with CAV and assess secondary outcomes including CAV progression and impact on immunosuppression and transplant rejection.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date March 28, 2023
Est. primary completion date March 28, 2023
Accepts healthy volunteers No
Gender All
Age group 19 Years to 80 Years
Eligibility Inclusion Criteria: - Heart transplant patients 19-80 years of age - Coronary allograft vasculopathy grade 1 or 2 documented by left heart cardiac catheterization - Able to provide signed informed consent Exclusion Criteria: - Cardiac allograft vasculopathy (CAV) grade 3 - Rejection requiring IV therapy in the prior 3 months - Infection requiring IV therapy in the prior 3 months - Active liver disease or hepatic dysfunction, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the upper limit of normal - Current or recent use of a PCSK9 inhibitor within the past 12 weeks - Organ transplant recipient other than heart - Renal dysfunction defined as glomerular filtration rate (GFR) < 20 ml/min - Known allergy to evolocumab or its components

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Evolocumab
Enrolled study participants will be treated with evolocumab (Repatha) 140 mg injected subcutaneously every 2 weeks for 52 weeks. All study participants will receive instruction on correct self-administration by research pharmacists. Study drug will be mailed to patients on a monthly basis for self-administration by patients. The evolocumab dose (140 mg every 2 weeks) will remain constant for the duration of the study. Side effects will be assessed on a quarterly basis. Serious adverse events considered related to treatment, death, and pregnancy will all result in immediate discontinuation of the study drug.

Locations

Country Name City State
United States University of Nebraska Medical Center Omaha Nebraska

Sponsors (2)

Lead Sponsor Collaborator
University of Nebraska Amgen

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent Change in Serum LDL (mg/dL) After 12 Weeks of Evolocumab The primary outcome measure for this study was percent change in LDL from baseline after 12 weeks of evolocumab therapy. Serum LDL was measured at baseline and after 12 weeks of evolocumab therapy. This primary endpoint was used in prior phase 2 trials investigating evolocumab in other patient populations. Wilcoxon matched-pairs signed rank test was used for statistical assessment. 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT02964026 - Study of Clinical Outcomes Associated With the Pulmonary Artery Catheter (PAC) in Cardiac Surgery Patients N/A
Active, not recruiting NCT05096299 - OCS Heart EXPAND + CAP Continued Follow-Up
Completed NCT02323321 - International EXPAND Heart Pivotal Trial N/A
Not yet recruiting NCT05025774 - Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise
Recruiting NCT05933083 - MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation N/A
Completed NCT03150095 - Health Coaching to Improve Self-Management in Thoracic Transplant Candidates N/A
Active, not recruiting NCT02554578 - Impact of mHealth in Heart Transplant Management N/A
Terminated NCT03346278 - Text Message Intervention to Improve Cardiac Rehab Participation N/A
Active, not recruiting NCT05741723 - OCS DCD Heart + CAP Continued Follow-Up
Completed NCT03831048 - Donors After Circulatory Death Heart Trial N/A
Completed NCT04615182 - Donor After Circulatory Death Heart CAP Trial N/A
Completed NCT02597543 - Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction Phase 4
Recruiting NCT05824364 - Exercise aNd hEArt Transplant N/A
Enrolling by invitation NCT05390411 - Seeking Objectivity in Allocation of Advanced Heart Failure (SOCIAL HF) Therapies Trial N/A
Recruiting NCT04770012 - AERIAL Trial: Antiplatelet Therapy in Heart Transplantation Phase 3
Terminated NCT01769443 - Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation Phase 2
Completed NCT00466804 - Noninvasive Methods to Monitor Graft Survival in Heart Transplant Patients N/A
Recruiting NCT06426173 - Effect of Resistance Training in Patients on the Waiting List for Heart Transplant N/A
Not yet recruiting NCT05459181 - HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC) N/A
Terminated NCT01485757 - Prospective L-arginine Study Phase 1